A Quality By Design (QbD) Prospect in Fabrication of PLGA-based
Antipsychotic Long-acting Microspheres: An Alternative to Combination
Therapy

Akanksha      Singh; Rajkiran      Narkhede; Rajani      Athawale

doi:10.2174/0124522716306759240522112102

Abstract

Background: Discontinuation and poor compliance with long-term oral medicine are major therapeutic issues in psychosis treatment. Poorer long-term outcomes may result from non-compliance as well as a higher chance of relapse. In order to sustain therapeutic drug plasma levels, co-administration of oral antipsychotics is necessary for commercially available longacting injections of second-generation antipsychotics, as they have a lag period of approximately three weeks during the drug release process.

Methods: Poly(lactic-co-glycolic acid) (PLGA) encapsulated microspheres loaded with risperidone were fabricated in the current research for intramuscular administration. The single emulsion solvent evaporation technique was applied for the fabrication of microspheres. Risperidone microspheres were prepared using PLGA grade 75:25. Particle size, drug content and entrapment efficiency with a central composite design were the main optimization parameters for the formulation. The microspheres were characterized by different techniques, namely Fourier transform infrared spectroscopy (FT-IR), differential scanning calorimetry (DSC), X-ray diffractometry (XRD), scanning electron microscopy (SEM), and transmission electron microscopy (TEM). The drug content, entrapment efficiency, morphology, particle size, and in vitro release profiles, along with release kinetics of the risperidone microspheres, were studied.

Results and Discussion: The microspheres produced by the single emulsion solvent evaporation approach show smooth and spherical morphology, with particle size ranging from 3 μm to 6 μm, drug content of 99.7%, and entrapment efficiency of 98.2% with little burst release of 3% to 10%, providing drug release for 45 days and exhibiting zero order release kinetics and Korsmeyer- Peppas model for non-fickian drug release from the polymeric matrix. By applying the Quality by Design (QbD) approach and formulation parameters, microspheres with appropriate particle size, morphology, enhanced drug content, entrapment efficiency and desirable drug release profile for depot formulation can be obtained successfully.

Conclusion: The optimized microspheres, in comparison to the marketed Risperdal Consta™, show enhanced potential for a better depot formulation, which can further improve patient compliance.

« Previous Next »

Graphical Abstract

[1]
Rubio MD, Drummond JB, Meador-Woodruff JH. Glutamate receptor abnormalities in schizophrenia: implications for innovative treatments. Biomol Ther  2012; 20(1): 1-18.
 [http://dx.doi.org/10.4062/biomolther.2012.20.1.001] [PMID: 24116269]

[2]
Rössler W, Joachim Salize H, van Os J, Riecher-Rössler A. Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol  2005; 15(4): 399-409.
 [http://dx.doi.org/10.1016/j.euroneuro.2005.04.009] [PMID: 15925493]

[3]
Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry  1997; 154(4): 1-63.
 [http://dx.doi.org/10.1176/ajp.154.4.1]

[4]
Su ZX, Shi YN, Teng LS, et al. Biodegradable poly(D, L-lactide-co-glycolide) (PLGA) microspheres for sustained release of risperidone: Zero-order release formulation. Pharm Dev Technol  2011; 16(4): 377-84.
 [http://dx.doi.org/10.3109/10837451003739297] [PMID: 20370594]

[5]
Baweja R, Sedky K, Lippmann S. Long-acting antipsychotic medications. Curr Drug Targets  2012; 13(4): 555-60.
 [http://dx.doi.org/10.2174/138945012799499785] [PMID: 22250654]

[6]
Kane JM, Aguglia E, Altamura AC, et al. Guidelines for depot antipsychotic treatment in schizophrenia. Eur Neuropsychopharmacol  1998; 8(1): 55-66.
 [http://dx.doi.org/10.1016/S0924-977X(97)00045-X] [PMID: 9452941]

[7]
Barnes TRE, Curson DA. Long-term depot antipsychotics. A risk-benefit assessment. Drug Saf  1994; 10(6): 464-79.
 [http://dx.doi.org/10.2165/00002018-199410060-00005] [PMID: 7917075]

[8]
Nayak RK, Doose DR, Nair NPV. The bioavailability and pharmacokinetics of oral and depot intramuscular haloperidol in schizophrenic patients. J Clin Pharmacol  1987; 27(2): 144-50.
 [http://dx.doi.org/10.1002/j.1552-4604.1987.tb02175.x] [PMID: 3680566]

[9]
Schwendeman SP, Shah RB, Bailey BA, Schwendeman AS. Injectable controlled release depots for large molecules. J Control Release  2014; 190: 240-53.
 [http://dx.doi.org/10.1016/j.jconrel.2014.05.057] [PMID: 24929039]

[10]
Wan F, Yang M. Design of PLGA-based depot delivery systems for biopharmaceuticals prepared by spray drying. Int J Pharm  2016; 498(1-2): 82-95.
 [http://dx.doi.org/10.1016/j.ijpharm.2015.12.025] [PMID: 26688034]

[11]
Fleischhacker WW. Second-generation antipsychotic long-acting injections: Systematic review. Br J Psychiatry  2009; 195(S52): s29-36.
 [http://dx.doi.org/10.1192/bjp.195.52.s29] [PMID: 19880914]

[12]
Chaurasia S, Mounika K, Bakshi V, Prasad V. 3-month parenteral PLGA microsphere formulations of risperidone: Fabrication, characterization and neuropharmacological assessments. Mater Sci Eng C  2017; 75: 1496-505.
 [http://dx.doi.org/10.1016/j.msec.2017.03.065] [PMID: 28415443]

[13]
Davis JM, Metalon L, Watanabe MD, Blake L. Depot antipsychotic drugs: Place in therapy. Drugs  1994; 47(5): 741-73.
 [http://dx.doi.org/10.2165/00003495-199447050-00004] [PMID: 7520856]

[14]
Kane JM. Pharmacologic treatment of schizophrenia. Biol Psychiatry  1999; 46(10): 1396-408.
 [http://dx.doi.org/10.1016/S0006-3223(99)00059-1] [PMID: 10578454]

[15]
Johnson D. Long-term drug treatment of psychosis: Observations on some current issues. Int Rev Psychiatry  1990; 2(3-4): 341-53.
 [http://dx.doi.org/10.3109/09540269009026605]

[16]
Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophr Bull  1991; 17(2): 325-51.
 [http://dx.doi.org/10.1093/schbul/17.2.325] [PMID: 1679255]

[17]
Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: Efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry  2003; 160(6): 1125-32.
 [http://dx.doi.org/10.1176/appi.ajp.160.6.1125] [PMID: 12777271]

[18]
Adams CE, Fenton MKP, Quraishi S, David AS. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry  2001; 179(4): 290-9.
 [http://dx.doi.org/10.1192/bjp.179.4.290] [PMID: 11581108]

[19]
Davis JM, Janicak PG, Singla A, Sharma RP. Antipsychotic Drugs and Their Side-Effects Chap Maintenance medication.  London: Academic Press 1993; pp. 183-203.
 [http://dx.doi.org/10.1016/B978-0-12-079035-7.50019-1]

[20]
Ramstack M, Grandolfi GP, Mannaert E, D’Hoore P, Lasser RA. Long-acting risperidone: Prolonged-release injectable delivery of risperidone using medisorbò microsphere technology. Schizophr Res  2003; 60(1): 314.
 [http://dx.doi.org/10.1016/S0920-9964(03)80260-8]

[21]
Davis SS, Hardy JG, Newman SP, Wilding IR. Gamma scintigraphy in the evaluation of pharmaceutical dosage forms. Eur J Nucl Med  1992; 19(11): 971-86.
 [http://dx.doi.org/10.1007/BF00175865] [PMID: 1425786]

[22]
Cheng YH, Illum L, Davis SS. A poly(d,l-lactide-co-glycolide) microsphere depot system for delivery of haloperidol. J Control Release  1998; 55(2-3): 203-12.
 [http://dx.doi.org/10.1016/S0168-3659(98)00056-X] [PMID: 9795060]

[23]
Knox ED, Stimmel GL. Clinical review of a long-acting, injectable formulation of risperidone. Clin Ther  2004; 26(12): 1994-2002.
 [http://dx.doi.org/10.1016/j.clinthera.2004.12.009] [PMID: 15823763]

[24]
Love RC, Conley RJ. Long-acting risperidone injection. Am J Health Syst Pharm  2004; 61(17): 1792-800.
 [http://dx.doi.org/10.1093/ajhp/61.17.1792] [PMID: 15462250]

[25]
Leal A, Rosillon D, Mehnert A, Jarema M, Remington G. Healthcare resource utilization during 1‐year treatment with long‐acting, injectable risperidone. Pharmacoepidemiol Drug Saf  2004; 13(11): 811-6.
 [http://dx.doi.org/10.1002/pds.978] [PMID: 15386706]

[26]
D’Souza S, Faraj JA, Giovagnoli S, DeLuca PP. Development of risperidone PLGA microspheres. J Drug Deliv  2014; 620464.
 [http://dx.doi.org/10.1155/2014/620464]

[27]
Orkoula MG, Kontoyannis CG. Non-destructive quantitative analysis of risperidone in film-coated tablets. J Pharm Biomed Anal  2008; 47(3): 631-5.
 [http://dx.doi.org/10.1016/j.jpba.2008.01.049] [PMID: 18359600]

[28]
Giovagnoli S, Blasi P, Ricci M, Rossi C. Biodegradable microspheres as carriers for native superoxide dismutase and catalase delivery. AAPS PharmSciTech  2004; 5(4): 1-9.
 [http://dx.doi.org/10.1208/pt050451] [PMID: 15760048]

[29]
Gref R, Quellec P, Sanchez A, Calvo P, Dellacherie E, Alonso MJ. Development and characterization of CyA-loaded poly(lactic acid)–poly(ethylene glycol)PEG micro- and nanoparticles. Comparison with conventional PLA particulate carriers. Eur J Pharm Biopharm  2001; 51(2): 111-8.
 [http://dx.doi.org/10.1016/S0939-6411(00)00143-0] [PMID: 11226817]

[30]
Khang G, Rhee JM, Jeong JK, et al. Local drug delivery system using biodegradable polymers. Macromol Res  2003; 11(4): 207-23.
 [http://dx.doi.org/10.1007/BF03218355]

[31]
Hausberger AG, DeLuca PP. Characterization of biodegradable poly(d,l-lactide-co-glycolide) polymers and microspheres. J Pharm Biomed Anal  1995; 13(6): 747-60.
 [http://dx.doi.org/10.1016/0731-7085(95)01276-Q] [PMID: 7669829]

[32]
Edlund U, Albertsson AC. Degradable polymer microspheres for controlled drug delivery. Degradable aliphatic polyesters  2002; 67-112.
 [http://dx.doi.org/10.1007/3-540-45734-8_3]

[33]
Okada H. One- and three-month release injectable microspheres of the LH-RH superagonist leuprorelin acetate. Adv Drug Deliv Rev  1997; 28(1): 43-70.
 [http://dx.doi.org/10.1016/S0169-409X(97)00050-1] [PMID: 10837564]

[34]
D’Souza SS, Selmin F, Murty SB, Qiu W, Thanoo BC, DeLuca PP. Assessment of fertility in male rats after extended chemical castration with a GnRH antagonist. AAPS PharmSci  2004; 6(1): 94-9.
 [http://dx.doi.org/10.1208/ps060110] [PMID: 15198511]

[35]
Okada H, Doken Y, Ogawa Y, Toguchi H. Preparation of three-month depot injectable microspheres of leuprorelin acetate using biodegradable polymers. Pharm Res  1994; 11(8): 1143-7.
 [http://dx.doi.org/10.1023/A:1018936815654] [PMID: 7971715]

[36]
Woo BH, Kostanski JW, Gebrekidan S, Dani BA, Thanoo BC, DeLuca PP. Preparation, characterization and in vivo evaluation of 120-day poly(d,l-lactide) leuprolide microspheres. J Control Release  2001; 75(3): 307-15.
 [http://dx.doi.org/10.1016/S0168-3659(01)00403-5] [PMID: 11489318]

[37]
Woo BH, Na KH, Dani BA, Jiang G, Thanoo BC, DeLuca PP. In vitro characterization and in vivo testosterone suppression of 6-month release poly(D,L-lactide) leuprolide microspheres. Pharm Res  2002; 19(4): 546-50.
 [http://dx.doi.org/10.1023/A:1015168301339] [PMID: 12033393]

[38]
Chue P, Eerdekens M, Augustyns I, et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol  2005; 15(1): 111-7.
 [http://dx.doi.org/10.1016/j.euroneuro.2004.07.003] [PMID: 15572280]

[39]
Burgess D, Hickey A. Microspheres. Drugs and the Pharmaceutical Sciences  2005; 149: 305-53.
 [http://dx.doi.org/10.1201/9780849350610.ch9]

[40]
Hickey T, Kreutzer D, Burgess DJ, Moussy F. Dexamethasone/PLGA microspheres for continuous delivery of an anti-inflammatory drug for implantable medical devices. Biomaterials  2002; 23(7): 1649-56.
 [http://dx.doi.org/10.1016/S0142-9612(01)00291-5] [PMID: 11922468]

[41]
Park TG. Degradation of poly(lactic-co-glycolic acid) microspheres: effect of copolymer composition. Biomaterials  1995; 16(15): 1123-30.
 [http://dx.doi.org/10.1016/0142-9612(95)93575-X] [PMID: 8562787]

[42]
Beg S, Rahman M, Panda SS. Pharmaceutical QbD: Omnipresence in the product development lifecycle. Eur Pharm Rev  2017; 22(1): 58-64.

[43]
Singh B, Beg S. Quality by design in product development life cycle. Chronicle Pharmabiz  2013; 22: 72-9.

[44]
Bhoop BS, Raza K, Beg S. Developing “optimized” drug products employing “designed” experiments. Chemical Industry Digest  2013; 23: 70-6.

[45]
Rose F, Wern JE, Ingvarsson PT, et al. Engineering of a novel adjuvant based on lipid-polymer hybrid nanoparticles: A quality-by-design approach. J Control Release  2015; 210: 48-57.
 [http://dx.doi.org/10.1016/j.jconrel.2015.05.004] [PMID: 25957906]

[46]
Chu D, Tian J, Liu W, Li Z, Li Y. Poly(lactic-co-glycolic acid) microspheres for the controlled release of huperzine A: In vitro and in vivo studies and the application in the treatment of the impaired memory of mice. Chem Pharm Bull  2007; 55(4): 625-8.
 [http://dx.doi.org/10.1248/cpb.55.625] [PMID: 17409558]

[47]
Su Z, Sun F, Shi Y, et al. Effects of formulation parameters on encapsulation efficiency and release behavior of risperidone poly(D,L-lactide-co-glycolide) microsphere. Chem Pharm Bull  2009; 57(11): 1251-6.
 [http://dx.doi.org/10.1248/cpb.57.1251] [PMID: 19881277]

[48]
Al-Kassas R. Design and in vitro evaluation of gentamicin–Eudragit microspheres intended for intra-ocular administration. J Microencapsul  2004; 21(1): 71-81.
 [http://dx.doi.org/10.1080/02652040310001619992] [PMID: 14718187]

[49]
Gao L, Zhang D, Chen M. Drug nanocrystals for the formulation of poorly soluble drugs and its application as a potential drug delivery system. J Nanopart Res  2008; 10(5): 845-62.
 [http://dx.doi.org/10.1007/s11051-008-9357-4]

[50]
Liu WH, Song JL, Liu K, Chu DF, Li YX. Preparation and in vitro and in vivo release studies of Huperzine A loaded microspheres for the treatment of Alzheimer’s disease. J Control Release  2005; 107(3): 417-27.
 [http://dx.doi.org/10.1016/j.jconrel.2005.03.025] [PMID: 16154224]

[51]
Berkland C, Kipper MJ, Narasimhan B, Kim KK, Pack DW. Microsphere size, precipitation kinetics and drug distribution control drug release from biodegradable polyanhydride microspheres. J Control Release  2004; 94(1): 129-41.
 [http://dx.doi.org/10.1016/j.jconrel.2003.09.011] [PMID: 14684277]

[52]
Yildiz BC, Kayan A. Ti(IV)-silyliminophenolate catalysts for ϵ-caprolactone and L-Lactide polymerization. Sustain Chem Pharm  2021; 21100416.
 [http://dx.doi.org/10.1016/j.scp.2021.100416]

[53]
Kayan GÖ, Kayan A. Polycaprolactone composites/blends and their applications especially in water treatment. ChemEngineering  2023; 7(6): 104.
 [http://dx.doi.org/10.3390/chemengineering7060104]

[54]
Daniel JSP, Veronez IP, Rodrigues LL, Trevisan MG, Garcia JS. Risperidone – Solid-state characterization and pharmaceutical compatibility using thermal and non-thermal techniques. Thermochim Acta  2013; 568: 148-55.
 [http://dx.doi.org/10.1016/j.tca.2013.06.032]

[55]
Karavelidis V, Giliopoulos D, Karavas E, Bikiaris D. Nanoencapsulation of a water soluble drug in biocompatible polyesters. Effect of polyesters melting point and glass transition temperature on drug release behavior. Eur J Pharm Sci  2010; 41(5): 636-43.
 [http://dx.doi.org/10.1016/j.ejps.2010.09.004] [PMID: 20863892]

[56]
Karavelidis V, Bikiaris D, Avgoustakis K. New thermosensitive nanoparticles prepared by biocompatible pegylated aliphatic polyester block copolymers for local cancer treatment. J Pharm Pharmacol  2015; 67(2): 215-30.
 [http://dx.doi.org/10.1111/jphp.12337] [PMID: 25616209]

[57]
Beslikas T, Gigis I, Goulios V, Christoforides J, Papageorgiou GZ, Bikiaris DN. Crystallization study and comparative in vitro-in vivo hydrolysis of PLA reinforcement ligament. Int J Mol Sci  2011; 12(10): 6597-618.
 [http://dx.doi.org/10.3390/ijms12106597] [PMID: 22072906]

[58]
Papageorgiou GZ, Beslikas T, Gigis J, Christoforides J, Bikiaris DN. Crystallization and enzymatic hydrolysis of PLA grade for orthopedics. Adv Polym Technol  2010; 29(4): 280-99.
 [http://dx.doi.org/10.1002/adv.20194]

[59]
Raman C, Berkland C, Kim KK, Pack DW. Modeling small-molecule release from PLG microspheres: Effects of polymer degradation and nonuniform drug distribution. J Control Release  2005; 103(1): 149-58.
 [http://dx.doi.org/10.1016/j.jconrel.2004.11.012] [PMID: 15773062]

[60]
Ramstack J, Grandolfi G, Mannaert E, D’Hoore P, Lasser RA. Risperdal Consta TM: prolonged-release injectable delivery of risperidone using Medisorb VR microsphere technology. Abstr Am Assoc Pharm Sci  2002; 4: S1.

[61]
Siafaka PI, Barmpalexis P, Lazaridou M, et al. Controlled release formulations of risperidone antipsychotic drug in novel aliphatic polyester carriers: Data analysis and modelling. Eur J Pharm Biopharm  2015; 94: 473-84.
 [http://dx.doi.org/10.1016/j.ejpb.2015.06.027] [PMID: 26159838]

[62]
Hoffman AS. The origins and evolution of “controlled” drug delivery systems. J Control Release  2008; 132(3): 153-63.
 [http://dx.doi.org/10.1016/j.jconrel.2008.08.012] [PMID: 18817820]

[63]
Wu F, Jin T. Polymer-based sustained-release dosage forms for protein drugs, challenges, and recent advances. AAPS PharmSciTech  2008; 9(4): 1218-29.
 [http://dx.doi.org/10.1208/s12249-008-9148-3] [PMID: 19085110]

[64]
Mitragotri S, Burke PA, Langer R. Overcoming the challenges in administering biopharmaceuticals: Formulation and delivery strategies. Nat Rev Drug Discov  2014; 13(9): 655-72.
 [http://dx.doi.org/10.1038/nrd4363] [PMID: 25103255]

[65]
Fu X, Ping Q, Gao Y. Effects of formulation factors on encapsulation efficiency and release behaviour in vitro of huperzine A-PLGA microspheres. J Microencapsul  2005; 22(7): 705-14.
 [http://dx.doi.org/10.1080/02652040500162196] [PMID: 16421082]

[66]
Huang Z, Chen X, Fu H, et al. Formation mechanism and in vitro evaluation of risperidone-containing PLGA microspheres fabricated by ultrafine particle processing system. J Pharm Sci  2017; 106(11): 3363-71.
 [http://dx.doi.org/10.1016/j.xphs.2017.07.010] [PMID: 28736289]

[67]
Hu Z, Liu Y, Yuan W, Wu F, Su J, Jin T. Effect of bases with different solubility on the release behavior of risperidone loaded PLGA microspheres. Colloids Surf B Biointerfaces  2011; 86(1): 206-11.
 [http://dx.doi.org/10.1016/j.colsurfb.2011.03.043] [PMID: 21524893]

[68]
Georgiadis MC, Kostoglou M. On the optimization of drug release from multi-laminated polymer matrix devices. J Control Release  2001; 77(3): 273-85.
 [http://dx.doi.org/10.1016/S0168-3659(01)00510-7] [PMID: 11733095]

[69]
Iordanskii AL, Zaikov GE, Berlin AA. Diffusion kinetics of hydrolysis of biodegradable polymers. Weight loss and control of the release of low molecular weight substances. Polym Sci Ser D Glues Sealing Mater  2015; 8(3): 211-8.
 [http://dx.doi.org/10.1134/S1995421215030053]

[70]
Nanaki S, Barmpalexis P, Iatrou A, Christodoulou E, Kostoglou M, Bikiaris D. Risperidone controlled release microspheres based on poly (lactic acid)-poly (propylene adipate) novel polymer blends appropriate for long acting injectable formulations. Pharmaceutics  2018; 10(3): 130.
 [http://dx.doi.org/10.3390/pharmaceutics10030130] [PMID: 30104505]

[71]
Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm  1983; 15(1): 25-35.
 [http://dx.doi.org/10.1016/0378-5173(83)90064-9]

[72]
Crank J. The mathematics of diffusion. Oxford University Press 1979.

[73]
Barmpalexis P, Kachrimanis K, Malamataris S. Statistical moments in modelling of swelling, erosion and drug release of hydrophilic matrix-tablets. Int J Pharm  2018; 540(1-2): 1-10.
 [http://dx.doi.org/10.1016/j.ijpharm.2018.01.052] [PMID: 29407874]

Rights & Permissions Print Cite

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/0124522716306759240522112102	Print ISSN 2452-2716
Publisher Name Bentham Science Publisher	Online ISSN 2452-2724

Current Applied Polymer Science

A Quality By Design (QbD) Prospect in Fabrication of PLGA-based Antipsychotic Long-acting Microspheres: An Alternative to Combination Therapy

Abstract Play Pause

Graphical Abstract

Related Journals

Related Books

Abstract